MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved ...
The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...
The FDA approved Exact Sciences’ Cologuard Plus multitarget stool DNA test to screen adults aged 45 years or older at average risk for colorectal cancer, according to a company press release. Compared ...
Positive and Negative Predictive Value of a Non-Endoscopic Molecular Barrett’s Esophagus Detection Test in Screening Eligible Adults: Results from a Large Multicenter Population Based Clinical Trial ...
A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday ...
Nearly a decade after the original Cologuard test received premarket approval from the FDA and became a blockbuster hit as a screening tool for colorectal cancer, its maker Exact Sciences is planning ...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance ...
MADISON (WKOW) — Exact Sciences has launched its new "Cologuard Plus" test. This test is gaining attention as the most accurate non-invasive colorectal screening test currently available. The ...
Exact SciencesEXAS stock crashed to a three-year low Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer test. The company already developed a blood-based ...
Exact Science’s Michelle Beidelschies, PhD, reveals how a multi-biomarker class multi-cancer early detection test (MCED) blood test can help health systems expand detection across more cancers earlier ...
Cologuard Plus™ test raises the performance bar with sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity Cologuard Plus test will minimize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback